The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias-Reference-Cited by-同舟云学术

The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias

Published:2016-02-25 Issue:13 Volume:7 Page:16650-16662
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Zabkiewicz Joanna¹,Gilmour Marie¹,Hills Robert¹,Vyas Pares²,Bone Elizabeth³,Davidson Alan³,Burnett Alan¹,Knapper Steven¹

Affiliation:

1. Department of Haematology, Experimental Cancer Medicine Centre (ECMC), Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK

2. Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK

3. Chroma Therapeutics, Abingdon, UK

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances Potency;Journal of Pharmacology and Experimental Therapeutics;2024-01-22

2. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies;Signal Transduction and Targeted Therapy;2023-02-17

3. In the Pipeline: Emerging Therapy for Acute Myeloid Leukaemia;Pathogenesis and Treatment of Leukemia;2023

4. Repurposing From Oncology to Cardiology: Low-Dose 5-Azacytidine Attenuates Pathological Cardiac Remodeling in Response to Pressure Overload Injury;Journal of Cardiovascular Pharmacology and Therapeutics;2020-12-02

5. Present and future perspectives for targeting histone modifications in therapy;Histone Modifications in Therapy;2020